{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:27:04Z","timestamp":1789820824087,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","award":["91636703"],"award-info":[{"award-number":["91636703"]}],"id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.atherosclerosis.2025.119234","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:28:21Z","timestamp":1747250901000},"page":"119234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C"],"prefix":"10.1016","volume":"406","author":[{"given":"Charlotte","family":"Nigmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Draxler-Dworzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Baumgartner-Kaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller-Sacherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Arbeiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-8370","authenticated-orcid":false,"given":"Susanne","family":"Greber-Platzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.atherosclerosis.2025.119234_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2025.119234_bib2","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2025.119234_bib3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for Clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the european atherosclerosis society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119234_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S2352-4642(21)00095-X","article-title":"Advances in familial hypercholesterolaemia in children","volume":"5","author":"Reijman","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119234_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/ATVBAHA.112.252700","article-title":"Vascular function during prolonged progression and regression of atherosclerosis in mice","volume":"33","author":"Miller","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119234_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119234_bib7","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2017.06.058","article-title":"Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations","volume":"70","author":"Stein","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119234_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.119234_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119234_bib10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.119234_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117525","article-title":"Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN","volume":"392","author":"Reijman","year":"2024","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119234_bib12","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American heart association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119234_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2019.02.001","article-title":"Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-Apheresis in Turkey: results of a nationwide survey (A-HIT1 registry)","volume":"13","author":"Kayikcioglu","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119234_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12887-022-03192-7","article-title":"Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia","volume":"22","author":"Lischka","year":"2022","journal-title":"BMC Pediatr"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119234_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the Pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2025.119234_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1744-9987.13856","article-title":"Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"26","author":"Duell","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119234_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.119234_bib18","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.119234_bib19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.119234_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph15111389","article-title":"Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","volume":"15","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119234_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2025.119234_bib22","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.119234_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","article-title":"Marked plaque regression in homozygous familial hypercholesterolemia","volume":"327","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119234_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119234_bib25","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:21:17Z","timestamp":1778473277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"alternative-id":["S0021915025001327"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119234","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119234"}}